Comparative Pharmacology
Head-to-head clinical analysis: FLUONID versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUONID versus LOCOID.
FLUONID vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid